This study integrated longitudinal antibiotic prescribing data with clinical microbiology and whole-genome sequencing for bacteraemia isolates collected in the Calgary Health Zone (CHZ) between 2006 and 2022. Prescribing trends were quantified for community and hospital settings and modelled alongside antimicrobial resistance (AMR) phenotypes detected in bloodstream isolates. Temporal changes were summarised using average annual percentage change (AAPC).
The analysis included 7,271 Staphylococcus aureus, 1,609 Enterococcus faecalis, 801 Enterococcus faecium, 11,363 Escherichia coli, and 2,319 Klebsiella pneumoniae isolates associated with bacteraemia episodes in the CHZ from 2006–2022. Genomic clusters (referred to as strains) were identified using StrainGST and linked to known sequence types (STs) or clonal complexes (CCs). Strain-level incidence and resistance phenotypes were calculated for each lineage.
Incidence and resistance were modelled using negative-binomial and binomial regression. Isolates were stratified by onset: community-onset (specimens collected ≤48 hours after admission) and hospital-onset (>48 hours after admission). The study assessed associations between prescribing rate changes and AMR trends, and examined which bacterial strains were responsible for observed shifts. Temporal trends were reported as AAPC with confidence intervals and p-values.
Between 2010 and 2022, fluoroquinolone prescribing declined in both community (AAPC = -6.8%, 95% CI -8.1 to -5.4; p < 0.0001) and hospital settings (AAPC = -5.1%, 95% CI -6.5 to -3.7; p < 0.0001). This reduction in fluoroquinolone use was accompanied by a significant decrease in fluoroquinolone resistance among Gram-positive species in the CHZ. The temporal association reported in the source suggests prescribing reductions coincided with declines in resistance phenotypes for several clinically important antibiotics.
Resistance among S. aureus isolates to clinically important agents — including cloxacillin, ciprofloxacin, erythromycin, and clindamycin — declined from 2006 to 2022. The overall decrease was driven largely by reductions in hospital-onset S. aureus bacteraemia. The average annual percentage change for clinically important resistance in S. aureus hospital-onset cases was reported as AAPC = -16.0% (95% CI -19.3% to -12.7%; p < 0.0001), indicating a substantial downward trend over the study interval.
In E. coli, ceftriaxone and ciprofloxacin resistance were concentrated within particular lineages, notably ST131 and the emerging ST1193. ST1193 showed a steady increase in incidence, particularly among community-onset bacteraemia, with AAPC = 17.7% (95% CI 0.0% to 30.0%; p < 0.0001). Within ST131, sublineages defined by extended-spectrum beta-lactamase (ESBL) genes shifted over time: CTX-M-27–producing ST131 strains increased between 2008 and 2022 (AAPC = 23.8%, 95% CI 17.4% to 30.5%; p < 0.0001), while CTX-M-14–producing ST131 declined between 2013 and 2022 (AAPC = -15.9%, 95% CI -21.3% to -10.2%; p < 0.0001).
These strain-level changes paralleled an increase in community cephalosporin prescribing between 2010 and 2022 (AAPC = 7.3%, 95% CI 4.2% to 10.5%; p < 0.0001), suggesting shifts in drug selection pressure in the community may relate to the evolving distribution of ESBL-producing lineages.
Among K. pneumoniae isolates, the hypervirulent lineage ST23 was the most commonly observed strain in the dataset (N = 88). ST23 showed an increasing incidence trend between 2006 and 2019 with an AAPC of 3.0% (95% CI -2.8% to 9.2%), indicating a rising presence though the confidence interval crosses zero. The report does not provide detailed resistance phenotype shifts for K. pneumoniae beyond lineage counts and incidence trends in the source text.
The study highlights contrasting AMR trends between Gram-positive and Gram-negative pathogens and demonstrates that these dynamics are shaped at the strain level. Key implications reported by the authors include the need for antimicrobial stewardship that targets multiple drug classes rather than single agents; robust genomic surveillance to detect and track emergent resistant lineages (for example, ST1193 and CTX-M–producing ST131); and public health interventions that extend beyond hospital settings into the community, given the rise of community-onset resistant strains.
The source notes that individual-level patient data cannot be shared due to Alberta Health Services privacy practices, but summary and synthetic datasets, analysis code, and genomic data are available via provided repositories (GitHub and ResistanceDB). The Institutional Review Board of the University of Calgary approved the study. The authors declared no competing interests. Specific numerical details, subgroup analyses beyond those reported, or additional outcomes not stated in the source were not reported.